Mitochondrial targeting cyclometalated iridium scaffold antitumor drugs

Area of Science:

• Medicinal Chemistry
• Nanotechnology
• Biochemistry

Background:

• Conventional metallodrugs like cisplatin face challenges including drug resistance and toxicity.
• Mitochondria are crucial for tumor cell survival, making them a key target for cancer therapy.
• Cyclometalated iridium(III) complexes offer unique photophysical properties and targeted biological activity.

Purpose of the Study:

• To systematically review recent advances in mitochondrial-targeted antitumor cyclometalated iridium scaffolds.
• To highlight molecular design strategies and their implementation in cancer treatment.
• To explore the potential of these complexes in chemotherapy, immunotherapy, and photodynamic therapy.

Main Methods:

• Compilation and analysis of recent research on iridium(III) complexes.
• Focus on molecular design principles for mitochondrial targeting.
• Review of therapeutic applications including chemotherapy, immunotherapy, and photodynamic therapy.

Main Results:

• Mitochondrial-targeted iridium(III) complexes demonstrate tunable ligand affinity and low dark toxicity.
• These complexes show potential for stimulus-responsive cancer treatments.
• Exploitation in various therapeutic modalities including chemotherapy, immunotherapy, and photodynamic therapy.

Conclusions:

• Mitochondrial-targeted cyclometalated iridium(III) complexes represent a promising next generation of anticancer agents.
• Further research into drug delivery, optimization, and clinical translation is warranted.
• These scaffolds offer significant potential for innovative cancer therapy strategies.